|
Age*, mean ± SD (years)
|
41.1 ± 11.6
|
41.2 ± 11.9
|
40.1 ± 8.7
|
|
Gender, n (%)
| | | |
|
Male
|
139 (94.6%)
|
126 (95.5%)
|
13 (86.7%)
|
|
Female
|
8 (5.4%)
|
6 (4.5%)
|
2 (13.3%)
|
|
Hereditary bleeding disorder types, n (%)
| | | |
|
Hemophilia A
|
113 (76.9%)
|
106 (80.3%)
|
7 (46.7%)
|
|
Hemophilia B
|
19 (12.9%)
|
14 (10.6%)
|
5 (33.3%)
|
|
VWD
|
8 (5.4%)
|
6 (4.5%)
|
2 (13.3%)
|
|
Glanzmann
|
1 (0.7%)
|
1 (0.8%)
|
0 (0%)
|
|
Other disorders
|
6 (4.1%)
|
5 (3.8%)
|
1 (6.7%)
|
|
HIV co-infection, n (%)
|
6 (4.1%)
|
5 (3.8%)
|
1 (6.7%)
|
|
HBV co-infection, n (%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
|
Platelet count**, mean ± SD (109/L)
|
200.0 ± 59.3
|
197.8 ± 59.4
|
219.8 ± 56.6
|
|
Hemoglobin**, Median (IQR) (g/dL)
|
15.7 (14.3–16.9)
|
15.7 (14.4–16.9)
|
15.3 (11.1–17.3)
|
|
AST**, Median (IQR) (IU/L)
|
38 (27–55)
|
38 (27–55)
|
38 (32–76)
|
|
ALT**, Median (IQR) (IU/L)
|
42 (27–70)
|
42 (30–70)
|
46 (19–72.5)
|
|
HCV RNA*, mean ± SD (log10 IU/mL)
|
6.0 ± 0.8
|
5.9 ± 0.8
|
6.2 ± 0.5
|
|
Liver stiffness measurement (Metavir score)*, n (%)
| | | |
|
F0–F2
|
75 (54%)
|
66 (52.8%)
|
9 (64.3%)
|
|
F2–F4
|
33 (23.7%)
|
31 (24.8%)
|
2 (14.3%)
|
|
F4
|
31 (22.3%)
|
28 (22.4%)
|
3 (21.4%)
|
|
Cirrhosis, n (%)
| | | |
|
Non-cirrhotic
|
110 (74.8%)
|
99 (75%)
|
11 (73.3%)
|
|
Compensated cirrhosis
|
32 (21.8%)
|
29 (22.0%)
|
3 (20%)
|
|
Decompensated cirrhosis
|
5 (3.4%)
|
4 (3.0%)
|
1 (6.7%)
|
|
HCV genotype*, n (%)
| | | |
|
1
|
98 (68.1%)
|
89 (68.5%)
|
9 (64.3%)
|
|
2
|
2 (1.4%)
|
2 (1.5%)
|
0 (0%)
|
|
3
|
30 (20.8%)
|
27 (20.8%)
|
3 (21.4%)
|
|
4
|
4 (2.8%)
|
4 (3.1%)
|
0 (0%)
|
|
Mix
|
10 (6.9%)
|
8 (6.1%)
|
2 (14.3%)
|
|
Previous treatment experience, n (%)
| | | |
|
Treatment naïve
|
68 (46.3%)
|
61 (46.2%)
|
7 (46.7%)
|
|
Interferon-experienced
|
79 (53.7%)
|
71 (53.8%)
|
8 (53.3%)
|
|
DAA-experienced
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
